BioCorRx Inc. · OTC:BICX
BioCorRx — Investor Presentation (February 2017)
33 slides from BioCorRx's investor presentation, Feb 8, 2017
Slide 1: BioCorRx
| . BioCorRx
Slide 2: Safe Harbor Statement
ee BioCorRxet Safe Harbor Statement The information in this investor presentation may include forward-looking statements. These forward- looking statements generally are identified by the words "believe," "project," “estimate,” "become," "plan," “will,” and similar expressions. These forward-looking
Slide 3: Investment Highlights
| BioCorRxeg Investment Highlights ¥ The addiction market represents a multi-billion dollar, underserved market with few viable options for patients Y Two-pronged business model for treating addiction: * Development stage pharmaceutical products for alcohol use disorder (AUD) and opioid addiction +
Slide 4: Company Overview
BioCorRxe§ Company Overview Substance abuse and addiction treatment company offering a two-pronged approach to the treatment of substance abuse addiction oresremens faunas ahs BioCorRxef Holding a ioCorRxeg) BioCorRxe§ harmaceuticals [Recovery Program Developing a new injectable naltrexone Alcoholis
Slide 5: The Addiction Epidemic
The Addiction Epidemic ig Costs, Imperfect Soluti
Slide 6: The Addiction Epidemic
| BioCorRxeg The Addiction Epidemic “Opioid abuse and addiction have taken a devastating toll on American families. We must do everything we can to make new, innovative treatment options available that can help patients regain control over their lives,” said FDA Commissioner Robert M. Califf, M.D. a
Slide 7: Addiction Treatment Market
ioCorRx@# Addiction Treatment Market: Addiction treatment spending has grown faster than the total GDP inflation rate, the medical care inflation rate, and population growth. From 2008- 2014, growth in addiction treatment spending also exceeded growth in total health spending. Spending In 2015 addic
Slide 8: Traditional Treatments — Lower Success Rates
ees >. BioCorRx Traditional Treatments — Lower Success Rates Traditional treatment programs largely fall into two categories: 1) Counseling based treatments - constitute the majority * AAand various similar programs - rely heavily on group support * Reported success rates have been low — high relaps
Slide 9: Medication Assisted Treatment
er BioCorRxef Medication Assisted Treatment Strong shift towards combining medication and counseling “By its very definition, medication-assisted treatment has to include more than medication alone. It has to include counseling services and the other support services that are an important part of ef
Slide 10: The Big Three
De BioCorRx The Big Three The Most Common MAT Medications Include: 1) Methadone: + FA approved ‘+ Narcotic and addictive — significant withdrawals when ceasing use + Daity Dose * Opioid Derived (full agonist) 2) Suboxone/Buprenorphine + FDA approved + Narcotic and addictive - significant withdrawals
Slide 11: Naltrexone Science
BioCorRx Naltrexone Science Naltrexone is a unique medication which binds with receptors and prevents the release of Dopamine — reducing cravings for alcohol and drugs Naltrexone was approved by the FDA in 1984, in tablet form, for opioid addiction and approved subsequently in 1994 for alcohol use d
Slide 12: BioCorRx Drug Development
BioCorRx aa BioCorRx®: Drug Development Unlocking Value, Expanding Treatment Capacity»
Slide 13: BioCorRx Pharmaceuticals: BICX101
RO eT BioCorRx® Pharmaceuticals BICX101 (long lasting injectable naltrexone) + Partnered with TheraKine to complete development of a new injectable version of naltrexone using underlying patented and patent pending technology * Utilizing TheraKine’s patented micro-delivery technology * May be delive
Slide 14: Competitive Landscape
ee Competitive Landscape Vivitrol (Alkermes PLC, NASDAQ:ALKS) Long lasting injectable naltrexone product: + FDA approved sustained release naltrexone injection - lasts up to 30 days + Strong demand - projected ~$200 million in sales in 2016 + Parent Company Alkermes ~$9 billion market cap, Vivitrol
Slide 15: Advantages of BICX101 Over Vivitrol
Advantages of BICX101 Over Vivitrol® BICX401 is expected to have significant advantages over the only existing long acting FDA approved injectable naltrexone on the market ¥ Naltrexone in a suspended release injectable v Drug release expected to be longer-lasting Y Less painful administration: IM de
Slide 16: BioCorRx Pharmaceuticals: Naltrexone Implant
BioCorRx BioCorRx® Pharmaceuticals Naltrexone Implant Acquired North American rights to new implant formulations and Prodetoxone study data in 2016* + 3 month formula has been used in other countries as unlicensed product for several years with 6 month version just developed. + Data acquired for Pro
Slide 17: Competitive Landscape - Implants
ee BioCorRse Competitive Landscape - Implants Titan Pharmaceuticals (NASDAQ:TTNP) and Braeburn Pharmaceuticals Current buprenorphine implant product: FDA approved buprenorphine implant in May 2016- six- month subdermal implant developed by Titan Pharmaceuticals inert sn of = Braeburn is developing a
Slide 18: Advantages of New Naltrexone Implant
eee 5 Co: Advantages of New Naltrexone Implant Significant advantages over current buprenorphine implant products: Y Addresses both alcoholism and opioid addiction ¥ Biodegrades eliminating the need to remove and replace Y Non-addictive active pharmaceutical ingredient v Known to be effective agains
Slide 19: R&D & FDA Objectives & Milestones
BioCorRxeg R&D & FDA Objectives & Milestones * Retained Dr. David Gastfriend ~ previously served as VP of Scientific Communications for Alkermes; heavily involved with Vivitrol Hired to provide leadership, expert insight, and assistance with all FDA-related matters * Retained Dr. Bal S. Brar as a le
Slide 20: R&D & FDA Objectives & Milestones (cont.)
BioCorRx R&D & FDA Objectives & Milestones (cont.) * Retained Innovative Science Solutions, LLC, a leading scientific consulting firm, to help guide the Company's regulatory strategy for FDA submission Plans to file 505(b)(2) submission for FDA approval * Selected Covance Inc. as the Company's Contr
Slide 21: 505(b)(2) Advantages / Cost / Pathway
eee BoC oxRx a 505(b)(2) Advantages / Cost /Pathway + 505(b)(2) helps avoid unnecessary duplication of studies already performed on a previously approved (“reference” or “listed”) drug * Gives the FDA express permission to rely on data not developed by the NDA applicant + Less expensive and faster r
Slide 22: Revenue Forecast: Injectable naltrexone
BioConRxeg Recovery ogra Revenue Forecast: Injectable/sustained release naltrexone Near-Tei m t n 0919/2020 2021/ Market Penetration 1% 2% 3% Revenue $125-150M $300-500m $900m+ * Conservative assumptions based on current naltrexone reimbursement + Potential for higher reimbursement due to long lasti
Slide 23: The BioCorRx Recovery Program
BioCorRx yi The BioCorRx®:Recovery-Program Non-Addictive Medication-Assisted ake, n
Slide 24: The BioCorRx Recovery Program
SSSS_IL=_=_____ BioCorRx# The BioCorRx® Recovery Program — Non-Addictive Medication-Assisted Treatment (MAT) Proprietary Naltrexone Implant! - cleared for use under FDA compounding rules + Implant inserted in fatty tissue of abdomen + Simple outpatient procedure by licensed medical professional + Pr
Slide 25: The BioCorRx Recovery Program — Consumer Cycle
BioCorRxef The BioCorRx® Recovery Program — Consumer Cycle ‘Medication continues to work for several months while consumer heals Outpatient counseling physically and mentally program begins while In peer support program living a regular lifestyle Proprietary implant free of cravings for drugs surgic
Slide 26: Recovery Program vs Traditional Modalities
BioCorRxef BioCorRx® Recovery Program vs Traditional Modalities BioCorRx® Recovery] Alcohol : | feet cas, | meena | ‘Significantly Blocks Cravings ¥ N Y/N Outpatient & Discrete Y YN = Non-Narcotic, Non Addictive Y Y wa Return to Work immediately Y Y A ‘Combines Medication & Therapy y N Y/N
Slide 27: Target Business Model - MAT
BioConRxet Revavery Progra Target Business Model - MAT + Specific fees charged by providers and collected by BioCorRx are confidential and vary based on region and other factors + Can include higher upfront license fees with lower recurring per program sale fees, or higher recurring patient fees wit
Slide 28: Corporate Profile
ed —_ Busines a ifeye : Corporate Profile in a = = We Focused es
Slide 29: Management
.. Management BioCorRxef Brady Granier, BSN: CEO/President, Director + 4.years with BioCorRx Inc.; repositioned company as leader in the industry with the acquisition of TheraKine technology and R&D Initiative, assembled a team of addiction experts worldwide, extensive experience with treatment of p
Slide 30: Key Statistics
——EE———————— Es BioCorRx Key Statistics Key Financial Information ore BIcK Fiscal Year End Dec. 31 Price (2/3/17) $0.039 Market Cap (2/3/17) $7.0M Common Shares Outstanding 181.9 Total Options (avg. strike $0.04) 479M Total Warrants (avg. strike $0.60) 26M Revenue (TTM) $660 K Gross Profit (TTM) $52
Slide 31: Contact
Contact Management Brady Granier CEO/President [email protected] Lourdes Felix cFO/coO [email protected] BioCorRxeg BioCorRxe 2390 E. Orangewood Ave. Suite 575 Anaheim, CA (714) 462-4880 www.BioCorR: www. beataddict an
Slide 32: 32
32
Slide 33: Appendix: Patent Portfolio Continued
Caen C0: )x 1 Appendix: Patent Portfolio Continued Sincudes further development of speci formation and drug patent includes further relevant patents dependent upon these cited through continuation or dvsion or expansion from PCT into National Phases